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ProliferationGrb2-assosiated binder (Gab) family proteins are docking molecules that can interact with receptor tyrosine
kinases (RTKs) and cytokine receptors and bind several downstream signalling proteins. Studies in several cell
types have shown that Gab1 may have a role in signalling mediated by the two RTKs epidermal growth factor
(EGF) receptor (EGFR) and Met, the receptor for hepatocyte growth factor (HGF), but the involvement of Gab1
in EGFR and Met signalling has not been directly compared in the same cell. We have studied mechanisms of
activation and role in mitogenic signalling of Gab1 in response to EGF and HGF in cultured rat hepatocytes.
Gab1, but not Gab2, was expressed in the hepatocytes and was phosphorylated upon stimulation with EGF or
HGF. Depletion of Gab1, using siRNA, decreased the ERK and Akt activation, cyclin D1 expression, and DNA
synthesis in response to both EGF and HGF. Studies of mechanisms of recruitment to the receptors showed
that HGF induced co-precipitation of Gab1 and Met while EGF induced binding of Gab1 to Grb2 but not to
EGFR. Gab1 activation in response to both EGF and HGF was dependent on PI3K. While EGF activated Gab1
and Shc equally, within the same concentration range, HGF very potently and almost exclusively activated
Gab1, having only a minimal effect on Shc. Collectively, our results strongly suggest that although Gab1 interacts
differently with EGFR and Met, it is involved in mitogenic signalling mediated by both these growth factor
receptors in hepatocytes.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Receptor tyrosine kinases (RTKs) located at the cell membrane
mediate regulation of a number of essential cellular processes, including
stimulation of proliferation andmigration, enhanced survival, and altered
differentiation, through activation of different intracellular signalling
pathways [1]. Upon ligand-induced activation, the RTKs recruit several
signalling proteins that serve as mediators, ampliﬁers or coordinators of
the signals [1–3]. Some of these are docking proteins which interact
with the RTKs and play essential roles in the signal transduction by
providing docking platforms for proteins involved in the downstream
pathways [4–6].
The Grb2-associated binder (Gab) protein family belongs to a group
of docking proteins which act downstream of RTKs and cytokine
receptors [7–9]. They have structural similarity to the insulin receptor
substrate (IRS) proteins [10]. Gab1 and Gab2 are the most widely
expressed of the mammalian Gab proteins [8,11]. They contain an N-idermal growth factor receptor;
associated binding protein 1;
Grb2, growth factor receptor-
, pleckstrin homology; PI3K,
ol (3,4,5)-trisphosphate; RTK,
22840202.
asrum).
ights reserved.terminal pleckstrin homology (PH) domain, several tyrosine-based
motifs, and a proline-rich region [9]. The PH domain can bind
phosphatidyl inositol-3,4,5-trisphosphate (PIP3) on the inner surface of
the plasma membrane. Once recruited by stimulation of RTKs, Gab1 can
be phosphorylated at several sites, some of which serve as binding sites
for signalling proteins such as the growth factor receptor-bound protein
2 (Grb2), SH2 domain-containing protein tyrosine phosphatase-2
(Shp2), RasGAP, the p85 subunit of phosphoinositide 3-kinase (PI3K),
and phospholipase C gamma (PLCγ) [12–16]. The proline-rich region of
Gab1, unlike Gab2, contains a Met-binding domain and is also involved
in binding of Grb2 [9].
Two of the RTKs that have been found to involve Gab1 in their
signalling are epidermal growth factor (EGF) receptor (EGFR) and
Met. EGFR is receptor for the growth factors of the EGF family [17],
while Met is receptor for hepatocyte growth factor (HGF) [3], also
termed scatter factor (SF) [18]. Investigations, including experiments
with knockdown of Gab1, suggest a role for this docking protein in
the function of EGFR and Met. The studies have indicated that Gab1 is
involved in EGFR-mediated mitogenic signalling, embryonic develop-
ment, and malignant transformation [12,19–23], and in Met-mediated
cell proliferation, migration, morphogenesis, and transformation [19,
20,22,24].
The mechanisms of Gab1 function in EGFR and Met signalling are
only partly understood. The EGFR does not bind Gab1 directly, but can
engage Gab1 via Grb2 [25–27], and there is evidence that activation of
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Akt pathways [27–30]. Unlike EGFR, Met can associate directly with
Gab1, through interactions between the proline-rich region of Gab1
and the phosphorylated Y1349 and Y1356 sites in the cytoplasmic tail
of Met [14,19,31]. In addition, Gab1 may interact indirectly with Met
via Grb2 bound to Y1356 [32,33]. Activated Met has also been found
to recruit a complex of Gab1/Grb2/SHP-2, leading to stimulation of the
Ras/ERK pathway [33]. PI3K can be recruited directly to the
multisubstrate docking site of Met or indirectly through Gab1 [34,35].
The relationship between, and relative importance of, Gab1 and Shc in
Met signalling has been a matter of debate [22,36–38].
While the biological role andmechanisms of Gab1 function have thus
been investigated, few studies have compared directly the involvement
of Gab1 in EGFR and Met signalling. Cultured rat hepatocytes might
provide a useful experimental model for such studies, since these cells
are highly responsive to both the EGF family mitogens and HGF [39,40]
and mechanisms of mitogenic signalling have been extensively studied
[41–43]. It has been reported that Gab1 is not expressed in cultured
hepatocytes [44,45], but, on the other hand, studies in transgenic mice
in vivo have strongly suggested biological roles of Gab1, including
Gab1/Erk-mediated attenuation of hepatic insulin-induced IRS-PI3K-
Akt signalling [46] and enhancement of liver regeneration by a concerted
effect of Gab1/Shp2 [47]. In the present study we found that, in contrast
to previously reported results [44,45], Gab1 was expressed in rat hepa-
tocytes in primary culture and was strongly phosphorylated in response
to EGF as well as HGF. Furthermore, in Gab1-depleted cells ERK and Akt
activation was attenuated and cyclin D1 expression and DNA synthesis
induced by these growth factors were decreased. Although further
studies indicated marked differences between EGFR and Met in their
interaction with Gab1, in terms of differential recruitment of Gab1 to
the receptor and a striking preference of Met for Gab1 phosphorylation
as compared to Shc, our results strongly suggest that Gab1 is involved
in mitogenic signalling in response to both EGF and HGF in hepatocytes.
2. Materials and methods
2.1. Materials
Dulbecco's Modiﬁed Eagle's Medium (DMEM), William's medium E,
penicillin and streptomycin were from BioWhittaker (Walkersville,
MD). HGF (recombinant human)was obtained fromMillipore (Billerica,
MA). EGF (frommouse), insulin, dexamethasone, collagenase (C-0130)
and collagen (type I from rat) were obtained from Sigma Chemical
Co. (St. Louis, MO). Wortmannin and U0126 were from Cell Signaling
(Beverly, MA). The primary antibodies anti-Gab1, anti-phospho-Gab1
(Tyr627), anti-pMet (Tyr1234/1235), anti-Akt, anti-phospho-Akt
(Ser473), anti-ERK1/2, anti-phosphoERK1/2 (Thr202/Tyr204), anti-
cyclin D1, anti-SHP2, anti-phospho-Shc (Tyr239/240) and anti-GAPDH
were from Cell Signaling (Beverly, MA), anti-Gab2 and anti-Grb2 were
from Santa Cruz Biotechnology (Santa Cruz, CA) and anti-phospho-
EGFR (Tyr1173) was from Invitrogen (Carlsbad, CA). Secondary goat
anti-mouse and goat anti-rabbit IgG HRP-conjugated antibodies were
purchased form Bio-Rad Laboratories (Hercules, CA). [6-3H]-thymidine
(20–30 Ci/mmol) was from Amersham Biosciences (Buckinghamshire,
UK). All other chemicals used were of analytical quality.
2.2. Cell isolation and culture
Male Wistar rats, 170–220 g, were fed ad libitum. Hepatocytes were
isolated by an in vitro collagenase perfusion technique [48] with
modiﬁcations as previously described [49]. Cell viability, measured as
the ability to exclude trypan blue, was above 90%. The hepatocytes were
plated at a density of 15,000/cm2 in Costar 6-well or 12-well plates. The
culture medium used was a serum-free 1:1 combination of William's
medium E and Dulbecco's Modiﬁed Eagle's Medium supplemented with
penicillin (67μg/ml), streptomycin (100μg/ml), collagen (3μg/ml), insulin(100 nM) and dexamethasone (25 nM). The cells were cultured in a
humidiﬁed 5% CO2 incubator at 37 °C. Ligand (EGF or HGF) was added
24 or 48h after plating, as indicated.
2.3. siRNA transfection
Isolated hepatocytes seeded in 12-well plates were transfected
with siRNA duplexes targeting rat Gab1 mRNA 3h after plating by the
use of Lipofectamine 2000. The medium was replaced (without
antibiotics) and 200 μl transfection mixture containing Lipofectamine
2000 (Invitrogen, Carlsbad, Ca) and Gab1-speciﬁc or non-targeting
ON-TARGET plus siRNA (Dharmacon, Lafayette, CO) in DMEM was
added per well (1 ml medium), giving a ﬁnal concentration of 60 nM
siRNA. Cells were incubated for 4 h and the medium replaced by
completemediumwith antibiotics. Transfected cells were then cultured
for 41h (48h after plating) and stimulated by EGF or HGF followed by
immunoblotting or measurement of DNA synthesis.
2.4. Immunoblotting
Hepatocyteswere stimulatedwith EGF or HGF for the indicated time
periods at 24 or 48 h of culturing. Total cell lysates were prepared by
boiling for 5min in Laemmli buffer (4% SDS, 20% glycerol and 120mM
Tris–HCl, pH6.8) and aliquots of 15 or 20 μg protein was separated on
10% polyacrylamide gels by electrophoresis (SDS-PAGE). The proteins
were transferred to nitro-cellulosemembranes using a semidry transfer
system (Bio-Rad). The membranes were blocked in Tris-buffered saline
containing 0.1% Tween 20 (TBST)with 5% non-fat drymilk solution and
incubated with the primary antibodies as indicated (in TBST with 5%
non-fat dry milk or BSA) overnight at 4 °C. The blots were then washed
3 times in TBST and incubated with HRP-conjugated secondary
antibodies at room temperature for 1h. The blots were visualized with
LumiGLO® (KPL, Gaithersburg, MD). Densitrometic analysis of immu-
noblots was obtained with Labworks Software (UVP, Cambridge, UK).
2.5. DNA synthesis
DNA synthesis induced by EGF or HGF was measured by thymidine
incorporation as previously described [50]. [6-3H] thymidine (1 μCi/ml)
was added to the cells together with the ligand at 48 h after plating.
The amount of radioactivity incorporated into DNA was measured
after 24h of incubation.
2.6. Subcellular fractionation
Preparation of cytosol and membrane fractions was done by using
the Qproteome Cell Compartment Kit from QIAGEN (QIAGEN Norway,
Oslo) by following the instructions in the handbook.
3. Results
3.1. Expression of Gab1 in rat hepatocytes
We found expression of Gab1, but not Gab2, in the hepatocytes. The
Western blot in Fig. 1A shows that in freshly isolated hepatocytes (0h)
and in hepatocytes kept in primary culture for 24h, the Gab1 antibody
detected a single 110 kD protein. In contrast, using a Gab2 antibody,
no band at the position of Gab2, i.e. around 90 kD, was observed. In a
control lysate from K562 cells, which are known to express both Gab1
and Gab2 [51], a 110 kD band (using the Gab1 antibody) and a 90 kD
band (with the Gab2 antibody) were detected (Fig. 1A). The level of
Gab1 in the hepatocytes increased with longer time in culture, as
assessed byWestern blotting (Fig. 1B), whereas Gab2 was not detected
at any time of culturing (3 h to 48 h) (data not shown). While this
demonstration of Gab1 in the hepatocytes disagrees with the previous
claim that Gab1 is not expressed in these cells [44,45,52], it is clearly
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Fig. 1. Gab1 is expressed in rat hepatocytes in primary culture. A. Immunoblotting for Gab1 and Gab2 in freshly isolated hepatocytes (0 h), hepatocytes 24 h after plating and K562 cells
(control cell line known to express both proteins). B. The expression of Gab1 during time in culture in unstimulated cells. Cells were harvested at the indicated time points and proteins
subjected to immunoblotting by using the indicated antibodies. C. The expresssion of Gab1 in EGF-and HGF-stimulated cells. 10 nM EGF or 1 nM HGF was added at 24 h. Cells were
harvested at the indicated time points and proteins subjected to immunoblotting using the indicated antibodies.
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consequences of liver-speciﬁc Gab1 knockout [46,47].
When EGF was added to the hepatocytes at 24 h after plating, the
expression of Gab1 decreased markedly (Fig. 1C). A similar, but less
sustained, downregulation of Gab1was seen in response to HGF. Others
have reported that HGF may induce ubiquitination of Gab1, leading to
its degradation [53]. In contrast to Gab1, Akt and Erk expression,
which also increased with time in culture (Fig. 1C), as previously
reported [54], was further upregulated by EGF and HGF (Fig. 1C).
3.2. Gab1 suppression reduces EGF- and HGF-induced Erk and Akt
phosphorylation, cyclin D1 expression, and DNA synthesis in hepatocytes
To study the role of Gab1 in mitogenic responses in the hepatocytes,
we examined how downregulation of Gab1 affected Erk and Akt
phosphorylation, cyclin D1 expression, and DNA synthesis in response
to HGF or EGF. Cells were transfected with a Gab1-directed siRNA or a
non-silencing control RNA, and the effects of EGF or HGF addition
were recorded. Fig. 2A shows the effects of two Gab1 siRNAs (si5 and
si20) on Gab1 expression; si20 caused an almost complete down-
regulation and was used in further experiments. As seen in Fig. 2B, the
phosphorylation of Erk and Akt in response to EGF or HGF was reduced
in Gab1-depleted cells, but not completely abolished. Furthermore, the
Gab1-speciﬁc siRNA also markedly attenuated the EGF- and HGF-
stimulated increases in cyclin D1 expression (Fig. 2C) and DNA
synthesis (Fig. 2D). Taken together, these results strongly support a
role of Gab1 in mediating growth factor-stimulated mitogenic res-
ponses in hepatocytes. This is consistent with previous ﬁndings in
liver regeneration, where Gab1 was required for full ERK activation,
upregulation of several cyclins, and hepatocyte proliferation [47].
3.3. Recruitment and activation of Gab1
In hepatocytes stimulated with HGF, immunoprecipitation with a
pMet antibody showed not only the presence of Met, but also co-
precipitation of pGab1, as detected with a pGab1 antibody (Fig. 3A,
top left panel). This indicates a complex of phosphorylated Met and
Gab1, consistentwith the evidence that Gab1 has aMet binding domainthat is essential for interaction between these molecules [19]. In
contrast, several attempts to co-immunoprecipitate EGFR and Gab1
failed to indicate a direct association between EGFR and Gab1 in EGF-
stimulated cells. Thus, no pGab1 was detected upon precipitation with
an EGFR antibody, and neither was there any evidence of co-
precipitation of EGFR in preparations precipitated with the pGab1
antibody (Fig. 3A, top right panel and bottom left panel). However,
using an antibody against Grb2 we could precipitate pGab1 as well as
SHP2 upon EGF treatment (Fig. 3A, bottom right panel). To further
study the recruitment of Gab1 in EGF-stimulated cells, we fractionated
the proteins from cytosol and membrane. In unstimulated cells, Gab1
was found in the cytosol, but following 3min of EGF stimulation most
of the Gab1 protein was detected in the membrane fraction (Fig. 3B,
top panel). The purity of the cytosol and membrane fractions was
ensured using antibodies detecting pERK and EGFR, respectively. In
cells treated with wortmannin, Gab1 was no longer translocated to
the membrane in response to EGF but remained in the cytosol
(Fig. 3B, bottom panel). This suggests that Gab1 in complex with Grb2
is bound to PIP3 in the membrane in EGF-stimulated cells.
It has previously been shown that in EGFR-mediated signalling PI3K
has an effect upstream of Gab1, in a mechanism where the PH domain
of Gab1 is essential for binding to the PIP3 in the membrane and for the
activation [25,28]. However, there is also some evidence that Gab1 may
be activated independently of PI3K [27]. The role of PI3K in Gab1
recruitment and activation induced byHGF is not clear and has been little
studied. Therefore, we examined how wortmannin, which inactivates
PI3K and thereby reduces the level PIP3 in the membrane, affected the
phosphorylation Gab1 in the hepatocytes induced by EGF and HGF. An
antibody speciﬁc for pY627 on Gab1 was used to monitor the effect,
since it has been shown that phosphorylation of Gab1 at Y627 is involved
in the binding of SHP2 to Gab1 and in the activation of downstream
signalling pathways [15,55]. Wortmannin partially inhibited the EGF-
induced phosphorylation of Gab1, whereas phosphorylation of Gab1
induced by HGF was nearly abolished (Fig. 3C). Wortmannin-treated
cells also showed a reduced phosphorylation of ERK in response to
HGF. As expected, wortmannin completely blocked the phosphorylation
of Akt in response to EGF or HGF. Furthermore, the highly speciﬁcMEK1/
MEK2 inhibitor U0126 did not affect the phosphorylation of Gab1 in
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Fig. 2.Reducing the level of Gab1 leads to a decrease in growth factor-induced cyclinD1 expression andDNA synthesis. Cellswere transfectedwith 60nMof a non-silencing siRNA (ns1) or
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is not necessary for Gab1 activation.
Collectively, the above results are consistent with data [7,19,25]
indicating that Gab1 can bind directly to Met, while it interacts with
EGFR indirectly via Grb2. The results also suggest that PI3K, but not
ERK, participates in Gab1 activation in response to EGF and, particularly,
HGF in the hepatocytes.
3.4. Time course of Gab1 phosphorylation in response to EGF and HGF
We next examined the time course of Gab1 phosphorylation upon
stimulation with EGF and HGF in the hepatocytes. In these experiments
we also recorded, in parallel, the phosphorylation of EGFR and Met, as
well as the phosphorylation of Akt and ERK. HGF is known to be more
potent than EGF [39,40,56,57]. A lower concentration of HGF (1 nM)
than EGF (10nM) was therefore used in these experiments. As seen in
Figs. 4A,B, Gab1 was strongly phosphorylated at Y627 in response to
either EGF or HGF. HGF consistently induced a more prolonged
phosphorylation of Gab1 as compared to the effect of EGF. This might
be a direct consequence of the difference in receptor activation, since
the EGF-stimulated activation of EGFR (at Y1173) was more transient
than theHGF-stimulated activation ofMet (at Y1234). HGF also induced
a much more sustained effect than EGF on the downstream signalling
molecules Akt and ERK. After 1 h, these proteins were still almostmaximally phosphorylated after exposure to HGF, while the effect of
EGF had a much shorter duration. These results show that whereas
both HGF and EGF are potent activators of Gab1 in hepatocytes, the
signals induced by HGF, both on Gab1 and on the downstream
pathways involving ERK andAkt, aremuchmore sustained as compared
to EGF.
3.5. Activation of Gab1 and Shc in response to EGF and HGF
Activated EGFR and Met provide docking sites able to interact with
several adaptor or docking proteins, including Gab1, Grb2, and Shc
[5,58]. Since the above results, in agreement with published data
[19,25] suggested differences in the interaction of Gab1 with EGFR and
Met, we examined more closely quantitative aspects of the effects of
EGF and HGF on Gab1 phosphorylation, and we also included studies
of activation of Shc by the two growth factors. While a role for Shc in
EGFR-stimulated pathways is well established [59,60] there are
discrepant results as to the involvement of Shc, and the relative
importance of Shc and Gab1, in Met signalling [22,36,38]. The time
course given in Fig. 5A shows that, whereas EGF strongly activated
Shc, only aminor activationwas seen in response toHGF. The difference
in EGF- and HGF-stimulated activation of Shc and Gab1 was further
demonstrated in the dose–response experiments in Fig. 5B. In contrast
to EGF, which activated Shc and Gab1 in the same concentration range
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Fig. 3. The activation of Gab1 by EGF and HGF is dependent on PI3K. A. Lysates prepared from cells stimulated for 5 min with HGF (1 nM) or EGF (10 nM) were subjected to
immunoprecipitation with the antibodies indicated below the blots. The complexes were resolved on SDS-PAGE and immunoblotted with the indicated antibodies. B. Immunoblotting
of the cytosol and membrane fractions from untreated (C) or EGF-stimulated cells (10 nM for 3 min) incubated with the indicated antibodies. Wortmannin (200 nM) was added
30 min before stimulation in the bottom panel. C. Cells were stimulated with 10 nM EGF or 1 nM HGF for the indicated time points 30 min after adding wortmannin (200 nM). Cells
were lysed andproteins subjected to immunoblottingusing the indicated antibodies. D. Cellswere stimulatedwith 10nMEGFor 1nMHGF for the indicated timepoints 30min after adding
U0126 (25 μM). Cells were lysed and proteins subjected to immunoblotting using the indicated antibodies.
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potency (ED50 at about 50pM),while therewas only a very slight effect
on Shc. Increasing the concentration of HGF beyond1nMdid not further
increase Shc phosphorylation (Fig. 5B, top right panel). These results
suggest that Met preferentially uses Gab1, as compared to Shc, in its
downstream signalling in the hepatocytes.
4. Discussion
In the present study we have shown that Gab1, but not Gab2, is
expressed in rat hepatocytes in primary culture, and that Gab1 is
phosphorylated in response to EGF and HGF, suggesting a role in the
signalling pathways activated by these growth factors. However, the
mechanisms of recruitment of Gab1 to EGFR and Met differed in part,
apparently reﬂecting direct binding of Gab1 toMet and indirect binding
via Grb2 to EGFR, while the results indicated that the Gab1 response to
both EGF and HGF was dependent on PI3K. The results also suggested
that the roles of Gab1 in signalling downstream of EGFR and Met werepartly different, since EGF activated Gab1 and Shc equally, within the
same concentration range, while HGF very potently and almost
exclusively activated Gab1, having only a minimal effect on Shc. Despite
these differences, depletion of Gab1 attenuated ERK and Akt activation,
cyclin D1 expression, and DNA synthesis in response to EGF as well as
HGF. Collectively, our results strongly suggest that although Gab1
interacts differently with EGFR and Met, it is involved in mitogenic sig-
nalling mediated by both these growth factor receptors in hepatocytes.
A role of Gab1 in pathways mediating stimulation of hepatocyte
proliferation is consistent with data from other experimental models.
Bard-Chapeau et al. showed that liver-speciﬁc knockout of Gab1or its
functional partner Shp2 suppressed Erk phosphorylation, expression
of several cyclins, and the regenerative hepatocyte proliferation after
partial hepatectomy inmice [47]. Involvement of Gab1 in proliferogenic
signalling is also supported by studies on other cells. In cells from head
and neck squamous cell carcinoma, suppression of Gab1 expression by
use of siRNA reduced the mitogenic stimulation by EGF and also
sensitized the cells to the EGFR tyrosine kinase inhibitor geﬁtinib [61].
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investigations on oral cancer cells did silencing of Gab1 completely
suppress the proliferative response to EGF, may suggest that Gab1
functions as an enhancer of mitogenic signalling. Alternatively, it is
conceivable that the low level of Gab1 still available is sufﬁcient for
the induction of proliferation, but a substantial regenerative DNA
synthesis was also seen in livers of Gab1 knockout mice [47]. A likely
interpretation is that Gab1 is an important contributor to the complex
protein interactions involved in mitogenic signalling. Additional
support for a promitogenic role has been obtained in experiments
where Gab1 has been overexpressed. This was shown to increase DNA
synthesis in response to HGF in HEK293 cells [62] and led to a
dramatically increased mitogenic effect of nerve growth factor in PC12
cells [63]. Thus, taken together, available evidence strongly suggests
that Gab1 is either a crucial mediator or a potent ampliﬁer in mitogenic
pathways.
In unstimulated cells, Gab1 is a cytosolic protein [25]. The sequence
of mechanisms causing its translocation to the plasma membrane and
recruitment to the receptors is not fully understood. It is well
established that Gab1 binds directly and speciﬁcally to Met [19], and
strong evidence indicates that Gab1 binds EGFR indirectly via Grb2
[7,25], although direct binding has also been suggested [26]. It has
also been found that PI3K activity is important for EGFR-mediatedphosphorylation of Gab1 [27,28], presumably by providing PIP3 in the
membrane in juxtaposition to the receptor, but little is known about
the role of PI3K for Gab1–Met interaction. In the hepatocytes we
found that HGF induced co-precipitation of pGab1 andMet. In contrast,
upon EGF stimulation we were unable to detect any co-precipitation of
Gab1 with EGFR, but Gab1 co-precipitated with both Grb2 and Shp2.
EGF also induced a massive translocation of Gab1 from the cytosol to
the plasma membrane. This translocation was blocked when PI3K was
inhibited by wortmannin. The role of PI3K in the Gab1 recruitment
was further documented by the ﬁnding that wortmannin inhibited
the Gab1 phosphorylation stimulated by EGF. It should be noted that
Gab1 phosphorylation in response to HGF was also inhibited by
wortmannin, and was actually more sensitive than the effect of EGF,
strongly suggesting involvement of PI3K in Met-mediated activation
of Gab1. The exactmechanism bywhich PI3K promotes Gab1 activation
is not clear. One possibility is that Gab1 directly bound toMet is further
stabilised by interaction of its PH domain with PIP3 in the membrane.
Alternatively, it is conceivable that PI3K is needed for the initial
activation of Gab1, facilitating Gab1/Met complex formation. Signalling
through the insulin receptor has also been found to require the PH
domain of Gab1 [64]. We consistently found that the phosphorylation
of Gab1 as well as Erk and Akt upon HGF stimulation was less rapid
but more prolonged than the EGF-induced effects. At the moment we
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Fig. 5. Activation of Gab1 and Shc in response to EGF and HGF. A. Cells were stimulatedwith 10nM EGF or 1nMHGF at 24h after plating and harvested at the indicated time points. Cells
were lysed and proteins subjected to immunoblotting using the indicated antibodies. Immunoblots shown are representative of three independent experiments. Graphs represent
densitometric quantiﬁcation of pGab1 and pShc based on three independent experiments ± SEM. B. Cells were stimulated increasing doses of EGF and HGF (in nM) for 5 min at 24 h
after plating. Cellswere lysed and proteins subjected to immunoblotting using the indicated antibodies. Immunoblots shown are representative of three independent experiments. Graphs
represent densitometric quantiﬁcation of pGab1 and pShc based on three independent experiments± SEM.
3292 M. Aasrum et al. / Biochimica et Biophysica Acta 1833 (2013) 3286–3294have no explanation for this difference and do not know if it reﬂects
differential kinetics in the activation mechanisms, but this question is
currently being studied further in our laboratory.
To examine further the differences between the roles of Gab1 in
EGFR- and Met-mediated signalling, we compared the activation of
Gab1 and Shc in response to EGF and HGF. The function of Shc as an
important docking protein in EGFR pathways, acting in concert with
Grb2, has been much studied and is well established [60]. In contrast,
there are discrepant results concerning the involvement of Shc in Met
signalling, and the relative importance of Shc and Gab1 is not known
[22,36,38]. Our experiments, where EGFR and Met could be stimulated
under exactly the same conditions in the hepatocytes, showed a
dramatic difference between the responses to EGF and HGF. While
EGF induced phosphorylation of Gab1 and Shc with almost identical
dose–response curves, HGF stimulated Gab1 markedly and at very lowconcentrations (ED50 around 50 pM), with only a very small effect on
Shc. These data strongly suggest that, at least in the hepatocytes, Met
preferentially uses Gab1 in its downstream signalling, as compared to
Shc. It is of interest that mutated Met, unable to bind Grb2 and Shc,
has been found able to induce Ras-dependent phosphorylation of ERK
[31], and direct interaction of Gab1 with oncogenic Met (Tpr-Met)
was both necessary and sufﬁcient to induce cell cycle progression [22].
Furthermore, in colorectal cancer cells overexpressing Met, Gab1 and
Shp2 are involved in promoting tumour growth, motility, and invasion
without the requirement of Grb2/Shc [38]. Our results are compatible
with a preferential use of Gab1 in Met-induced signalling.
EGFR andMet seem to have unique roles inmediating stimulation of
hepatocyte proliferation. Although they to a large extent use common
pathways, studies of liver regeneration upon selective gene silencing
of these receptors have indicated that EGFR and Met cannot fully
3293M. Aasrum et al. / Biochimica et Biophysica Acta 1833 (2013) 3286–3294compensate for each other [65,66]. Further studies are needed to
determine the role of Gab1 in the partly differentialmitogenic signalling
mediated by EGFR and Met in the liver.
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